Is the septic response good or bad?

Current Infectious Disease Reports

Volumn 9, Issue 5, 2007, Pages 366-373

  Wiersinga, Willem Joost ^b   van der Poll, Tom ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; BLOOD CLOTTING FACTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; FLAGELLIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 6; LIPOTEICHOIC ACID; MANNAN; MYELOID DIFFERENTIATION FACTOR 88; NICOTINIC RECEPTOR; OUTER MEMBRANE PROTEIN; PATTERN RECOGNITION RECEPTOR; PEPTIDOGLYCAN; PLACEBO; THROMBOPLASTIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; BLOOD CLOTTING; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE EXACERBATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; VAGUS NERVE;

EID: 34548786816     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0057-5     Document Type: Review

References (53)

1. Levy MM, Fink MP, Marshall JC, et al.: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256.
2. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005, 365:63-78.
3. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
4. Marshall JC: The staging of sepsis: understanding heterogeneity in treatment efficacy. Crit Care 2005, 9:626-628.
5. Vincent JL: Is the current management of severe sepsis and septic shock really evidence based? PLoS Med 2006, 3:e346.
6. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
7. Knapp S, Wieland CW, van 't Veer C, et al.: Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 2004, 172:3132-3138.
8. Wang X, Moser C, Louboutin JP, et al.: Toll-like receptor 4 mediates innate immune responses to Haemophilus influenzae infection in mouse lung. J Immunol 2002, 168:810-815.
9. Branger J, Knapp S, Weijer S, et al.: Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice. Infect Immun 2004, 72:788-794.
10. Mollen KP, Anand RJ, Tsung A, et al.: Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006, 26:430-437.
11. Tracey KJ, Fong Y, Hesse DG, et al.: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987, 330:662-664.
12. Fischer E, Marano MA, Van Zee KJ, et al.: Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992, 89:1551-1557.
13. van der Poll T, van Deventer SJ: Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999, 13:413-426, ix.
14. Ward PA: The dark side of C5a in sepsis. Nat Rev Immunol 2004, 4:133-142.
15. Czermak BJ, Sarma V, Pierson CL, et al.: Protective effects of C5a blockade in sepsis. Nat Med 1999, 5:788-792.
16. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
17. Liew FY, Xu D, Brint EK, O'Neill LA: Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005, 5:446-458.
18. Brint EK, Xu D, Liu H, et al.: ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004, 5:373-379.
19. Wald D, Qin J, Zhao Z, et al.: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003, 4:920-927.
20. Heumann D, Glauser MP, Calandra T: Monocyte deactivation in septic shock. Curr Opin Infect Dis 1998, 11:279-283.
21. Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6:813-822.
22. Hotchkiss RS, Tinsley KW, Swanson PE, et al.: Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A 1999, 96:14541-14546.
23. Hotchkiss RS, Chang KC, Swanson PE, et al.: Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000, 1:496-501.
24. Tracey KJ: Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007, 117:289-296.
25. Wang H, Yu M, Ochani M, et al.: Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
26. Wang H, Liao H, Ochani M, et al.: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004, 10:1216-1221.
27. van Westerloo DJ, Giebelen IA, Florquin S, et al.: The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis 2005, 191:2138-2148.
28. Pavlov VA, Ochani M, Gallowitsch-Puerta M, et al.: Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci U S A 2006, 103:5219-5223.
29. Huston JM, Ochani M, Rosas-Ballina M, et al.: Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 2006, 203:1623-1628.
30. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 2005, 131:417-430.
31. Wiersinga WJ, Levi M, van der Poll T: Coagulation in sepsis. In Mechanisms of Sepsis-induced organ dysfunction and recovery, vol. 44. Edited by Vincent JL. Heidelberg: Springer-Verlag; 2007:273-285.
32. Franco RF, de Jonge E, Dekkers PE, et al.: The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 2000, 96:554-559.
33. Aras O, Shet A, Bach RR, et al.: Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004, 103:4545-4553.
34. de Jonge E, Dekkers PE, Creasey AA, et al,: Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000, 95:1124-1129.
35. Creasey AA, Chang AC, Feigen L, et al.: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993, 91:2850-2856.
36. Taylor FB, Chang A, Ruf W, et al.: Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991, 33:127-134.
37. Van de Wouwer M, Collen D, Conway EM: Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004, 24:1374-1383.
38. Taylor FB Jr, Emerson TE Jr, Jordan R, et al.: Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988, 26:227-235.
39. Taylor FB Jr, Chang A, Esmon CT, et al.: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987, 79:918-925.
40. Bernard GR, Vincent JL, Laterre PF, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
41. Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik Hack C: Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001, 86:543-549.
42. Levi M, Ten Care H: Disseminated intravascular coagulation. N Engl J Med 1999, 341:586-592.
43. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al.: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33:564-573.
44. Wang H, Bloom O, Zhang M, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
45. Park JS, Svetkauskaite D, He Q, et al.: Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279:7370-7377.
46. Bouchon A, Facchetti F, Weigand MA, Colonna M: TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001, 410:1103-1107.
47. Gibot S, Kolopp-Sarda MN, Bene MC, et al.: Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004, 141:9-15.
48. Gibot S, Kolopp-Sarda MN, Bene MC, et al.: A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 2004, 200:1419-1426.
49. Hamerman JA, Tchao NK, Lowell CA, Lanier LL: Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 2005, 6:579-586.
50. Roger T, David J, Glauser MP, Calandra T: MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001, 414:920-924.
51. Calandra T, Echtenacher B, Roy DL, et al.: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000, 6:164-170.
52. Bozza FA, Gomes RN, Japiassu AM, et al.: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004, 22:309-313.
53. Al-Abed Y, Dabideen D, Aljabari B, et al.: ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severse sepsis. J Biol Chem 2005, 280:36541-36544.